Noticias de LLY_US
Noticias del mercado
Últimas noticias sobre LLY_US — 531 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Eli Lilly lanza Lormalzi en India, una terapia de administración mensual para el Alzheimer con deterioro leve. Se dirige a las placas amiloides para frenar el deterioro cognitivo, ya que se prevé que los casos de demencia se dupliquen para 2036.
Eli Lilly lanza Lormalzi, un fármaco contra el Alzheimer, en la India, que ofrece un tratamiento en fase inicial en medio de un creciente debate científico sobre sus beneficios reales. , Salud, Times Now
Eli Lilly brings monthly Alzheimer's therapy donanemab to India at ₹91,688 per vial
Why is Eli Lilly stock rallying today?
Is Eli Lilly and Company (LLY) A Good Stock To Buy Now?
Eli Lilly introduces amyloid plaque-targeting therapy for treatment of early symptomatic Alzheimer’s Disease in India
This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst
Eli Lilly stock advances as Lormalzi (donanemab) launch in India boosts sentiment
Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
Jim Cramer’s Take on 24 Stocks: Cisco, Eli Lilly, and Ford
Lilly data point to ‘maintenance’ strategies for GLP-1 weight loss
Lilly Alzheimer's drug donanemab launched in India (LLY:NYSE)
Lilly CEO David Ricks keeps eye on future while company celebrates history
Eli Lilly’s Foundayo and Lower-Dose Zepbound Helped Maintain Weight Loss in Patients Switching from Injectables
Eli Lilly Marks 150 Years With Food Security Drive And Investor Angles
Lilly at 150 as CEO Spotlights AI, Brain Science, GLP‑1 Advances
India gets its first Alzheimer’s therapy, will cost nearly a lakh per dose
Eli Lilly Launches Alzheimer's Drug Lormalzi Priced At Rs 91,688 Per Vial In India
Lilly celebrates 150 years on precipice of new era
Eli Lilly launches Alzheimer’s drug in India at $957 per vial
Página 1 de 27
